New generation of precision medicine in immuno-oncology, 
with proprietary STC platform, designed to generate 
first-in-class, proteomic-driven cancer vaccines.

OUR MISSION

Anticipating tumor’s evolution in cold solid tumors, which is currently the biggest unmet need in oncology

0 %

Of patients currently undergoing treatment for solid tumors will experience treatment failure and relapse within the 5 years.

In 2022, 10 million patients suffering from solid tumors found themselves in a therapeutic impasse leading to their death. 


This figure is set to rise by 70% by 2045.

CANCER IS
A MOVING TARGET

It constantly adapts and evolves to escape treatments.
The current arsenal of treatments is often inefficient by the absence of anticipation of tumor plasticity and resistance mechanisms.

OUR STIMULATED-TUMOR CELL (STC)  PLATFORM

is designed to generate ‘first-in-class’, off-the-shelf
therapeutic cancer vaccine fighting cancer recurrence.

MIMICS IN VITRO TUMORS RELAPSING CONDITIONS

CHARACTERIZED BY MULTI-OMICS ANALYSIS

TO GIVE BACK TO PATIENT THE ABILITY TO DESTROY TUMOR CELLS

REGARDLESS OF THEIR EVOLUTION

SAFELY ENSURES IMMUNE SYSTEM EDUCATION

PRECISION CANCER-RELATED
TARGETS

COLORECTAL CANCER

REMAINS A HUGE UNMET NEED WORLDWIDE

PATIENTS PER YEARS

incidence

mortality

2.000.000

3rd most common cancer

1.000.000

2nd CAUSE OF CANCER MORTALITY

COLORECTAL CANCER

REMAINS A HUGE UNMET NEED WORLDWIDE

PATIENTS PER YEARS

incidence

mortality

2.000.000

3rd most common cancer

1.000.000

2nd CAUSE OF CANCER MORTALITY

our team

Our team is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients.

With the support of

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens